Preface; Chapter 1; Impact of Personalized Medicine in Cancer; Abstract; Introduction; Foundation of Personalized Medicine; Pharmacogenetics; Pharmacodynamics; Pharmacokinetics; Pharmacokinetics or Pharmacodynamics; Pharmacogenomics; Toxicogenomics; Metabonomics; Pharmacoproteomics; Personalized Medicine in Cancer; Conclusion; Acknowledgments; Conflict of Interest; References; Chapter 2; Malignant Mesothelioma; Abstract; Introduction; Risk Factors; Asbestos; People Most at Risk of an Asbestos-Related Disease?; Non-Occupational Exposure; Treatment; Preventive Measures
Curative MeasuresSurgical; A. Malignant Mesothelioma of Tunica Vaginalis:; B. Malignant Pleural Mesothelioma; Chemotherapy; Radiotherapy; Recommendation; Targeted Therapy; Gene Therapy; Photodynamic Therapy; Immunotherapy; Virus Therapies; References; Chapter 3; The Role of Heat-Shock Proteins and Chaperonins in the Pathogenesis and Progression of Cancer; Abstract; Introduction; Molecular Chaperones; Chaperonins; Chaperones and Cancer; Hsp90; Hsp70; Hsp27; Chaperonins and Cancer; Overall Architecture of Chaperonins; CCT/TRiC and Cancer; Hsp60; Molecular Chaperones and the Immune Response
AcknowledgmentsReferences; Chapter 4; Biosynthesis of Lex Family Glycosphingolipids and its Gene Regulation: XIV. in Apoptotic Breast Carcinoma Cells; Abstract; Introduction and Discussion; Betulin and Betulinic Acid as Apoptotic Agents in Cancer Cells; Proper Drug Delivery Systems are Required to Kill Specific Cancer Cells; Summary; Acknowledgment; References; Chapter 5; Chromosome Instability as a Target for Cancer Therapeutics: Challenges of Mitotic Inhibitors; Abstract; Introduction; 1. The Spindle Assembly Checkpoint Maintains the Fidelity of Chromosome Segregation
1.1. Chromosome Segregation in Mitosis1.2. Spindle Assembly Checkpoint Machinery; 1.3. SAC Attenuation and Cancer; 2. Aneuploidy and Cancer; 2.1. Aneuploidy in Colorectal Cancer; 2.2. Aneuploidy in Ovarian Cancer; 2.3. Aneuploidy in Gastric Cancer; 3. Chromosome Dynamics and Cancer Therapeutics; 3.1. Microtubule-Targeting Agents; 3.2. Microtubule-Stabilizing Agents; 3.3. Microtubule-Destabilizing Agents; 3.4. Side Effects of Microtubule Inhibitors; 3.5. Target Molecule Inhibitors of Mitotic Components; 3.5.1. Aurora Kinase Inhibitors; 3.5.2. Polo-Like Kinase (PLK) Inhibitors
3.5.3. EG5 Inhibitors3.5.4. Centromere-Associated Protein-E (CENP-E) Inhibitors; Conclusion; Disclosure of Potential Conflict of Interest; References; Chapter 6; CD26-Targeted Therapy: A New Horizon in Malignant Pleural; Mesothelioma Management; Abstract; Introduction; Molecular Characterization of CD26; CD26 and Immune Function; Expression of CD26 in MPM; Clinical Relevance of CD26 Expression and MPM; MPM Cancer Cell Biology of CD26; CD26 and Cancer Stem Cells in MPM; Association of CD26 and Extracellular Matrix in MPM
Notes
Preclinical Proof-of-Concept (POC) Study of Anti-CD26 mAb Therapy for MPM
